Mutation at position 5628 in the mitochondrial tRNAAla gene in a Chinese pedigree with maternally diabetes mellitus

CURRENT STATUS: UNDER REVIEW

BMC Medical Genetics • BMC Series

Ke Li
Soochow University

Correo: likefggf@163.com Corresponding Author
ORCiD: https://orcid.org/0000-0002-2262-4936

Lijun Wu
Soochow University

Wei Lin
Soochow University

Tianlan Zhao
Soochow University

Qiang Qi
Soochow University

Jianjiang Liu
Soochow University

Weixin Chen
Soochow University

Wenjun He
Soochow University

Xiao Liu
Soochow University

Yuan Shi
Soochow University

DOI:
SUBJECT AREAS
  Medical Genetics

KEYWORDS
  Mitochondrial diabetes mellitus, mitochondrial DNA, mutation, Chinese, pathophysiology
Abstract

Background: To investigate the clinical, genetic and molecular characteristics of mitochondrial diabetes mellitus (MDM).

Methods: Resultant variants were evaluated for evolutionary conservation, allelic frequencies, and structural and functional consequences. The mitochondrial function including mitochondrial tRNAAla levels, protein synthesis, membrane potential, adenosine triphosphate (ATP) production, and reactive oxygen species (ROS) generation were measured using lymphoblastoid cell lines carrying the m.5628T>C mutation and 2 controls.

Results: We observed differences in the severity and age of onset in diabetes in affected maternally-related individuals, and through amolecular of the complete mitochondrial genome in this family, we identified a homoplasmic m.5628T>C mutation, located at conventional position 31 of tRNAAla, and we further detected distinct sets of mtDNA polymorphisms belonging to haplogroup L1. The identified mutation was further found be important for tRNA identity and stability. Using cellular models, we were able to determine that the respiratory deficiency caused arising as a consequence of the m.5628T>C mutation led to decreased efficiency of mitochondrial tRNAAla levels, protein synthesis, mitochondrial ATP synthesis and a reduced mitochondrial membrane potential. These mitochondrial dysfunctions caused an increase in the production of reactive oxygen species in the mutant cell lines.

Conclusions: These data provide a direct evidence that novel m.5628T>C mutation may be associated with MDM, thus, offering novel insights into the understanding of pathophysiology of MDM.

1. Background

Diabetes mellitus (DM) is a serious disease affecting upwards of 10% of the adult population in China [1,2]. This disease is multifactorial in nature, arising in a heterogeneous fashion owing to interactions between both genetic and environmental factors[3]. As mitochondrial diabetes mellitus (MDM) is a serious metabolic disease, and mitochondria serve asessential metabolic regulators within cells, these organelles are thought to be central to the pathogenesis of MDM [4]. As multiple studies have found that MDM risk can be transmitted in a matrilineal fashion, this further supports the potential for a
mitochondrial role in the development of this disease [2,5]. Indeed, some studies have proposed that mutations within mitochondrial tRNA sequences are key factors influencing the development of MDM and other metabolic diseases [6]. The 3243A>G, and m.3264T>C mutations in the tRNA^{Leu(UUR)}, the m.4291T>C mutation in the tRNA^{Ile}, the m.14709T>C and m.14692A>G mutations in the tRNA^{Glu}, and the m.10003T>C mutation in the tRNA^{Gly} have all been identified as potential mutations affecting MDM disease risk [7–12]. Exactly how these mutations ultimately contribute to disease onset, however, remains poorly understood, and as such there is a clear need for additional research into how mitochondrial dysfunction can act to mediate the onset or progression of MDM.

During a MDM genetic screening effort among 100 Chinese subjects, we were able to detect a T-to-C transition at position 5628 (conventional position 31) in the mitochondrial light(L)-strand in individuals with a familial history of matrilineal MDM transmission, and we further detected a set of variants belonging to the Asian haplogroup L1. The identified mutation is likely to disrupt normal base-pairing (31A–39U) for the tRNA^{Ala} anticodon in the mitochondrial heavy(H)-strand, thereby resulting in its abnormal functionality and structure, thereby likely resulting in mitochondrial dysfunction. We therefore sought to explore the significance of this m.5628T>C mutation using lymphoblastoid cell lines in order to observe the effects of this mutation on mitochondrial functionality, with a particular focus on processes including mitochondrial tRNA^{Ala} levels, protein synthesis, membrane potential, adenosine triphosphate (ATP) production, and reactive oxygen species (ROS) generation.

2. Methods
We initially recruited a Chinese MDM proband at the First Affiliated Hospital of Soochow University, China. After obtaining informed consent, we then conducted clinical evaluations and isolated blood samples from all family members who agreed to participate in this study. Any family or personal history of metabolic disease was identified through thorough historical and physical exams, and the proband and family members also underwent blood glucose testing at our hospital. In total, we recruited 100 control Chinese volunteers in order to screen for any mitochondrial tRNA mutations identical to those identified in the family the MDM patient. The Ethics Committees of Soochow...
University approved all study protocols. The principles of the Declaration of Helsinki were observed in this study [13].

2.2. Mitochondrial genome mutation analysis

We isolated total genomic and mitochondrial DNA from patient whole blood samples using a DNA Extraction Kit (QIAGEN: 51104). We then conducted PCR amplification of the whole mitochondrial genome of the proband subject with MDM (SZDM001-III-1), generating 24 overlapping PCR product fragments through the use of primers specific to the light and heavy strands, as in previous studies [12]. We then isolated these fragments and used an ABI 3700 automated DNA sequencer and a BigDye Terminator Cycle sequencing reaction kit to determine their sequences, which were compared to the updated consensus Cambridge sequence (GenBank accession number: NC_012920) [14].

In order to detect the m.5628T>C mutation of the mitochondrial tRNAAla gene, we used the following primers in order to specifically amplify the 5238–6050 region of the mitochondrial DNA via PCR: F: 5’-CTA ACC GGC TTT TTG CCC-3’ and R: 5’-ACC TAG AAG GTT GCC TGG CT-3’, as in previous reports [11]. We then isolated and assessed these fragments as in previous reports [12].

2.3. Phylogenetic analyses

In order to perform interspecific analyses, as in previous studies, we compared human mtDNA nucleotide variation frequencies to sequences in 16 other species of vertebrates in order to determine the appropriate conservation index (CI) [15,16]. Based on this CI value, it was then possible to determine what percentage of these 16 species exhibit a conserved wild-type base at the position of interest.

We further used an online application (www.mitotool.org/genomeRSRS.html) in order to determine the mitochondrial haplogroup of the proband and related individuals, consistent with current haplogroup nomenclature [17,18].

2.4. Cell culture

The Epstein-Barr virus was used in order to generate immortalized lymphoblastoid cell lines, as reported previously [12]. Immortalized cells from the proband (III–1) and another subject (III–10)
bearing the m.5628T>C mutation who had MDM, as well as from two controls (SZC1-control and SZC2-control) without the mutation but from the same haplogroup, were cultured using RPMI 1640 (Invitrogen) containing 10% FBS as well as 1% penicillin and streptomycin.

2.5 *mtRNA Northern blotting*

We extracted mitochondria from our control and mutant immortalized lines, and then isolated total mitochondrial RNA (mtRNA) using TRIzol, as in previous reports [19, 20]. We then electrophoretically separated 2 mg of this mtRNA onto a nylon membrane (Roche), prior to conducting a hybridization analysis using appropriate oligodeoxynucleotides as probes. We used digoxigenin (DIG)-labeled probes specific to 5S RNA, tRNA^{Ala}, tRNA^{Thr}, tRNA^{Glu}, or tRNA^{His}, and then used these for hybridization reactions and subsequent densitometric quantification, as in previous reports[19, 20].

2.6 *Western blotting*

Western blotting was conducted as in previous studies[19, 20]. Primary antibodies used herein include those targeting ND6(abcam ab81212), ND4(abcam ab219822), ATP6(proteintech 55313–1-AP), ND1(proteintech 19703–1-AP), and VDAC(proteintech 10866–1-AP). We used the peroxidase Affinipure goat anti-mouse IgG and goat anti-rabbit IgG (Jackson) as secondary antibodies, and an enhanced chemiluminescence (ECL) system (Millipore) was used for protein detection, after which densitometric calculations were performed.

2.7. *Assessment of ATP levels*

We utilized a CellTiter-Glo Luminescent cell viability assay (Promega, G7572) in order to assess levels of mitochondrial ATP based on a modified protocol provided by the manufacturer, with additional previously detailed modifications[20].

2.8. *Mitochondrial membrane potential measurement*

A JC–10 Mitochondrial Membrane Potential Microplate Assay Kit (Abcam, ab112134) was utilized based on provided protocols, as in previous studies, as a means of assessing the mitochondrial membrane potential [20]. Excitation/emission ratios of Ex/Em = 490/590 and 490/525nm were determined as a means of measuring ΔΨ_m in samples, with the relative ratio of these two values in mutants and controls being calculated to determine the ΔΨ_m value.
2.9. ROS measurements

The MitoSOX Red Mitochondrial Superoxide Indicator (Invitrogen, M36008) was used to assess ROS levels within live cells based on provided protocols, as in previous studies [21,22]. ROS production rates were determined based on geometric mean intensities in samples, and ratios of these intensity values between unstimulated and H$_2$O$_2$-stimulated cells were used to determine whether ROS generation was altered under oxidative stress conditions.

2.10. Statistical analysis

Microsoft Excel 2016 was used for all statistical testing, comparing values via unpaired, two-tailed t-tests. $P < 0.05$ was the threshold of significance unless otherwise indicated.

3. Results

3.1. Familial MDM presentation in a Han Chinese family

We identified a Chinese individual (SZDM001) that had visited the Diabetes Clinic at the First Affiliated Hospital of Soochow University (as shown in Figure 1). This patient underwent full physical examinations in an effort to identify any clinical or genetic factors associated with this instance of familial MDM. The patient was had been diagnosed with DM based upon standard diagnostic criteria: (1) fasting plasma glucose ≥ 7.0 mmol/L, (2) oral glucose tolerance ≥ 11.1 mmol/L, or (3) ≥6.5% glycated hemoglobin (HbA1c). Patients were diagnosed as having an elevated diabetes risk if they did not have a history of diabetes and met the following criteria: (1) fasting plasma glucose from 5.5–7.0 mmol/L, (2) 2 hour plasma glucose levels from 7.8–11.1 mmol/L, or (3) a HbA1c concentration of 5.7–6.4%. When a total of 13 matrilineal relatives were surveyed, a total of 5 were determined to have MDM (2 males and 3 females; as shown in Table 1). MDM symptoms were first diagnosed in these patients at the average age of 56 (range: 42–65), and other matrilineal relatives exhibited an elevated risk of diabetes based on the diagnostic criteria described above (data not shown). We did not observe any other significantly abnormal clinical conditions in these related individuals, such as cardiac, muscular, or neurological diseases. No other surveyed members of this family exhibited MDM, leading to our determination that this family exhibited matrilineally-inherited MDM.
3.2. Identification of MDM-associated mitochondrial mutations

We next sequenced the mitochondrial genomes of the proband patient SZDM001-III-1 patient in an effort to determine whether there were specific mitochondrial mutations underlying the observed matrilineal MDM pattern of inheritance. After comparing our sequences from this patient to the Cambridge consensus sequence, we detected a total of 67 single nucleotide polymorphisms in the mitochondrial genome, and additionally determined them to be of the Eastern Asian mitochondrial haplogroup L1. Of these 67 mutations, 9 were previously described D-loop variants, 2 were known 12S rRNA gene variants, 3 were known 16SrRNA variants, one was the newly characterized m.5628T>C tRNA\textsuperscript{Ala} mutation (as shown in Figure 2), 10 were known to be silent variants, and 8 were known missense mutations affecting protein-coding genes which were as follows:

m.3316T>C(Ala>Thr) in the ND1 gene, m.8860A>G (Thr>Ala) in the ATP6 gene, m.10609T>C (Met>Thr) in the ND4L gene, m.12406G>A(Val>Ile) and m.13928G>C(Ser>Thr) in ND5 gene, and m.14766C>T(Thr>Ile), m.15326A>G (Thr>Ala), and 15402C>T(Thr>Ile) in the CYTB gene. We next performed phylogenetic comparisons of these variants to known sequences of these same genes in 16 additional primate species in order to establish to what extent they were conserved. This comparison revealed the tRNA\textsuperscript{Ala} m.5628T>C mutation to be 100% conserved across species, whereas there was no clear functional significance of the other surveyed variants. We also did not detect this m.5628T>C mutation in 100 Chinese control subjects, and we thus found no evidence that that any detected mutations other than m.5628T>C were evolutionarily conserved.

3.3. Decreased tRNA\textsuperscript{Ala} levels

We found that mutant cell lines exhibited significantly decreased tRNA\textsuperscript{Ala} levels as compared with controls, with the 5S RNA used for normalization within cells (as shown in Figure 3). Indeed, mutant cells exhibited tRNA\textsuperscript{Ala} levels which were 80.41% (P<0.05) of those in control cells following normalization. In comparison, these mutant cells had steady-state tRNA\textsuperscript{Thr}, tRNA\textsuperscript{Glu}, and tRNA\textsuperscript{His} levels of 99.74%, 91.30% and 90.32%, respectively, relative to controls (as shown in Figure 3).

3.4. Reduced mitochondrial protein levels
We next assessed the levels of respiratory chain components encoded by the mitochondrial genome via Western blotting (as shown in Figure 4), using VDAC to control for equal protein loading. As shown in Figure 4, we found that levels of four proteins associated with mitochondrial translation in mutant cells were present at levels 8.05% - 26.04%, (average: 17.31%) relative to control cells (P<0.05). Cells bearing the m.5628T>C mutation also exhibited significant 18.60%, 26.04%, and 16.55% reductions in levels of the proteins ND6, ATP6, and ND1 proteins, respectively. These proteins contain between 4.6 and 8.8% alanine codons. In contrast, reductions of the ND4 protein which contains 5.7% alanine codons was relatively limited, at 8.05% relative to control.

3.5. ATP generation is reduced in mutant cells

We next assessed how the m.5628T>C mutation influences ATP generation in the mitochondria of affected cells using a luciferin/luciferase assay system. Cells were combined with media containing glucose, with or without oligomycin (to inhibit ATP synthase and promote glycolysis) or with a combination of pyruvate and 2-deoxy-d-glucose (to inhibit glycolysis and promote oxidative phosphorylation). As shown in Figure 5, we found that glycolysis activity was comparable between mutant and control cells, whereas ATP production via oxidative phosphorylation was significantly reduced in mutant cells relative to controls, with ATP production being 68.28% and 65.24% (average 66.76%) that observed in control cells (P = 0.009).

3.6. Mitochondrial membrane potential changes

We next assessed how m.5628T>C mutations altered mitochondrial membrane potential (ΔΨm) using the JC-10 fluorescent probe. As shown in Figure 6, we observed decreased ΔΨm values in mutant cells bearing the m.5628T>C mutation, with decreases averaging 69.16% of control ( 68.50% and 69.82%) (P = 0.002). We found that ΔΨm in mutant cells treated with FCCP were similar to values in control cells.

3.7. Elevated ROS production
We used flow cytometry to assess ROS production by mutant and control cells both upon H$_2$O$_2$ stimulation and at baseline. As shown in Figure 7, we found that mutant cells bearing the m.5628T>C mutation exhibited increased ROS production, with an average increase of 120.46% relative to controls ($P = 0.005$).

4. Discussion

Herein, we determined that the tRNA$^{\text{Ala}}$ m.5628T>C mutation is associated with the matrilineal transmission of MDM risk in a Chinese family. This m.5628T>C mutation affects coding at position 31 of this tRNA, and the presence of an adenine at this position is highly evolutionarily conserved among species, suggesting it is essential for normal tRNA function or pre-tRNA processing [23,24]. We were only able to detect this mutation in members of a Chinese family exhibiting MDM, and not in 100 control subjects. As shown in Table 2, we observed impaired glucose tolerance in 5 (2 males/3 females) out of a total of 13 matrilineal relatives, compared with the average penetrance of MDM in other Chinese families carrying the m.10003T>C and m.14692A>G mutations [11, 12]. Average age of diabetes onset in those with the m.5628T>C mutation was 56 (range: 42—65), while the average ages in those families with m.10003T>C and m.14692A>G mutations were 45 and 60 years, respectively [11,12]. As families with identical m.5628T>C mutations exhibit significant variability, this suggests that nuclear genes also play a role in modifying phenotypic manifestations of MDM in these individuals.

The observed mutation at the position 5628 (conventional position 31) is expected to lead to functional defects by interfering with normal base-pairing (31A–39U) in the mitochondrial H-strand of the tRNA$^{\text{Ala}}$ anticodon stem. These structural and functional shifts in this tRNA in turn mediate impaired mitochondrial functionality. We were able to utilize cell lines bearing this m.5628T>C mutation to provide clear evidence of multiple forms of mitochondrial dysfunction in these cells. Indeed, we found tRNA$^{\text{Ala}}$ levels to be clearly decreased in these mutant cells relative to controls (80.41%). It is possible that this mutated form of tRNA$^{\text{Ala}}$ has less metabolic stability, resulting in its more rapid degradation and thus reducing effective levels of the tRNA, as in the case of the of
tRNA^{Leu(UUR)} m.3243A > G mutation in the [25,26]. This mutation was also linked to significant reductions in 7 mitochondrially-encoded proteins, and all of these reductions were associated with a marked reduction in ATP synthesis, as well as increased oxidative stress that may be linked to defects in normal energetic processes. The observed 33.24% decrease in mitochondrial ATP in cells bearing the m.5628T>C mutation was similar to that in cells with the m.14692A>G mutation [11]. Impaired respiratory chain activity can also result in impaired mitochondrial membrane potential, which is closely linked to cell viability, and we found clear reductions in this potential by roughly 30.84% in mutant cells, indicating increased that mutant mitochondria were suffering from increased electron leakage during oxidative phosphorylation. These dysregulated mitochondrial activities were associated with excessive ROS generation in mutant cells, with a roughly 20.46% increase relative to controls. ROS production can in turn result in substantial damage to proximal proteins and other macromolecules, thereby impairing cell functionality.

Conclusion
This work is the first to detect a link between the m.5628T>C mutation and MDM. Disrupted normal metabolism of this tRNA as a result of this mutation appears to significantly impair normal mitochondrial functionality, with impaired mitochondrial protein synthesis, membrane potential, ATP production, and ROS generation being evident in mutated cells. As such, this m.5628T>C mutation is clearly a relevant candidate biomarker for heritable MDM risk, making it useful for molecular diagnostics. Our results therefore have the potential to improve current understanding of MDM, offering new insights into disease development and suggesting potential avenues for treatment or prevention.

Declarations

Abbreviations

MDM: mitochondrial diabetes mellitus; DM: diabetes mellitus; ATP: adenosine triphosphate; ROS: reactive oxygen species; CI: conservation index.

Ethics approval and consent to participate
All subjects were willing to participate in the study and the written informed consent for clinical
evaluations and genetic analysis were obtained from each participant. In addition, the protocol of the
study was approved by the medical ethics committee of the Institutional Review Board of the First
Affiliated Hospital of Soochow University.

Consent for publication
Written informed consent for publication of clinical details and/or clinical images was obtained from
all participants.

Availability of data and material
We used an online application (www.mitotool.org/genomeRSRS.html) in order to determine the
mitochondrial haplogroup.

Competing interests
The authors declare that they have no competing interests.

Funding
This work was supported by the national tutor system of Suzhou youth health mainstay (GGRC004) to
LW, the Project of Natural Science Research in Universities of Jiangsu Province (16KJB320010) to LW
and Suzhou Science and Education Program for Promoting Health (KJXW2016015) to KL.

Authors’ contributions
KL and LW contributed to conception or design of the work, data collection, data analysis and
interpretation, and drafting of the article. WL, TZ and QQ contributed to data collection, drafting of the
article, and critical revision of the article. JL, WH, YS, XL and WC contributed to the data analysis and
interpretation. KL contributed to conception or design of the work, data analysis and interpretation,
and critical revision of the article. All authors approved the final version to be published.

Acknowledgement
Not applicable.

References
[1]. Meetoo D, McGovern P, Safadi R. An epidemiological overview of diabetes across the world. Br J
[2]. Xu Y, Wang L, He J, Bi Y, Li M, Wang T, Wang L, Jiang Y, Dai M, Lu J, Xu M, Li Y, Hu N, Li J, Mi S, Chen CS, Li G, Mu Y, Zhao J, Kong L, Chen J, Lai S, Wang W, Zhao W, Ning G; 2010 China Noncommunicable Disease Surveillance Group. Prevalence and control of diabetes in Chinese adults. JAMA. 2013;310(9):948–59.

[3]. Owen KR, McCarthy MI. Genetics of type 2 diabetes. Curr Opin Genet Dev. 2007;17(3):239–44.

[4]. Benrahma H, Arfa I, Charif M, Bounaceur S, Eloualid A, Boulouiz R, Nahili H, Abidi O, Rouba H, Chadli A, Oudghiri M, Farouqui A, Abdelhak S, Barakat A. Maternal effect and familial aggregation in a type 2 diabetic Moroccan population. J Community Health. 2011 Dec;36(6):943–8.

[5]. Taylor RW, Turnbull DM. Mitochondrial DNA mutations in human disease. Nat Rev Genet. 2005;6(5):389–402.

[6]. Lott MT, Leipzig JN, Derbeneva O, Xie HM, Chalkia D, Sarmady M, Procaccio V, Wallace DC. mtDNA Variation and Analysis Using Mitomap and Mitomaster. Curr Protoc Bioinformatics. 2013;44:1.23.1–26.

[7]. van den Ouweland JM, Lemkes HH, Ruitenbeek W, Sandkuijl LA, de Vijlder MF, Struyvenberg PA, van de Kamp JJ, Maassen JA. Mutation in mitochondrial tRNA(Leu)(UUR) gene in a large pedigree with maternally transmitted type II diabetes mellitus and deafness. Nat Genet. 1992;1(5):368–71.

[8]. Damore ME, Speiser PW, Slonim AE, New MI, Shanske S, Xia W, Santorelli FM, DiMauro S. Early onset of diabetes mellitus associated with the mitochondrial DNA T14709C point mutation: patient report and literature review. J Pediatr Endocrinol Metab. 1999;12(2):207–13.

[9]. Suzuki Y, Suzuki S, Hinokio Y, Chiba M, Atsumi Y, Hosokawa K, Shimada A, Asahina T, Matsuoka K. Diabetes associated with a novel 3264 mitochondrial tRNA(Leu)(UUR) mutation. Diabetes Care. 1997;20(7):1138–40.

[10]. Wilson FH1, Hariri A, Farhi A, Zhao H, Petersen KF, Toka HR, Nelson-Williams C, Raja KM, Kashgarian M, Shulman GI, Scheinman SJ, Lifton RP. A cluster of metabolic defects caused by mutation in a mitochondrial tRNA. Science. 2004;306(5699):1190–4.

[11]. Wang M, Liu H, Zheng J, Chen B, Zhou M, Fan W, Wang H, Liang X, Zhou X, Eriani G, Jiang P, Guan MX. A Deafness- and Diabetes-associated tRNA Mutation Causes Deficient Pseudouridylation
at Position 55 in tRNAGlu and Mitochondrial Dysfunction. J Biol Chem. 2016;291(40):21029–21041.

[12]. Liu H, Li R, Li W, Wang M, Ji J, Zheng J, Mao Z, Mo JQ, Jiang P, Lu J, Guan MX. Maternally inherited diabetes is associated with a homoplasmic T10003C mutation in the mitochondrial tRNA(Gly) gene. Mitochondrion. 2015;21:49–57.

[13]. Skierka AS, Michels KB. Ethical principles and placebo-controlled trials - interpretation and implementation of the Declaration of Helsinki’s placebo paragraph in medical research. BMC Med Ethics. 2018;19(1):24.

[14]. Lin CY, Tsai LC, Hsieh HM, Huang CH, Yu YJ, Tseng B, Linacre A, Lee JC. Investigation of length heteroplasmy in mitochondrial DNA control region by massively parallel sequencing. Forensic Sci Int Genet. 2017 Sep;30:127–133.

[15]. Ji Y, Qiao L, Liang X, Zhu L, Gao Y, Zhang J, Jia Z, Wei QP, Liu X, Jiang P, Guan MX. Leber’s hereditary optic neuropathy is potentially associated with a novel m.5587T>C mutation in two pedigrees. Mol Med Rep. 2017;16(6):8997–9004.

[16]. Woischnik M, Moraes CT. Pattern of organization of human mitochondrial pseudogenes in the nuclear genome. Genome Res. 2002;12(6):885–93.

[17]. Xie S, Zhang J, Sun J, Zhang M, Zhao F, Wei QP, Tong Y, Liu X, Zhou X, Jiang P, Ji Y, Guan MX. Mitochondrial haplogroup D4j specific variant m.11696G > a(MT-ND4) may increase the penetrance and expressivity of the LHON-associated m.11778G > a mutation in Chinese pedigrees. Mitochondrial DNA A DNA Mapp Seq Anal. 2017;28(3):434–441.

[18]. Tanaka M, Cabrera VM, González AM, Larruga JM, Takeyasu T, Fuku N, Guo LJ, Hirose R, Fujita Y, Kurata M, Shinoda K, Umetsu K, Yamada Y, Oshida Y, Sato Y, Hattori N, Mizuno Y, Arai Y, Hirose N, Ohta S, Ogawa O, Tanaka Y, Kawamori R, Shamoto-Nagai M, Maruyama W, Shimokata H, Suzuki R, Shimodaira H. Mitochondrial genome variation in eastern Asia and the peopling of Japan. Genome Res. 2004;14(10A):1832–50.

[19]. Zhou M, Xue L, Chen Y, Li H, He Q, Wang B, Meng F, Wang M, Guan MX. A hypertension-associated mitochondrial DNA mutation introduces an m1G37 modification into tRNAMet, altering its structure and function. J Biol Chem. 2018;293(4):1425–1438.
[20]. Gong S, Peng Y, Jiang P, Wang M, Fan M, Wang X, Zhou H, Li H, Yan Q, Huang T, Guan MX. A deafness-associated tRNAHis mutation alters the mitochondrial function, ROS production and membrane potential. Nucleic Acids Res. 2014;42(12):8039–48.

[21]. Mahfouz R, Sharma R, Lackner J, Aziz N, Agarwal A. Evaluation of chemiluminescence and flow cytometry as tools in assessing production of hydrogen peroxide and superoxide anion in human spermatozoa. Fertil. Steril. 2009;92:819–827.

[22]. Winyard PG, Ryan B, Eggleton P, Nissim A, Taylor E, Lo Faro ML, Burkholz T, Szabó-Taylor KE, Fox B, Viner N, Haigh RC, Benjamin N, Jones AM, Whiteman M. Measurement and meaning of markers of reactive species of oxygen, nitrogen and sulfur in healthy human subjects and patients with inflammatory joint disease. Biochem Soc Trans. 2011;39(5):1226–32.

[23]. Abbott JA, Francklyn CS, Robey-Bond SM. Transfer RNA and human disease. Front Genet. 2014;5:158.

[24]. Yarham JW, Elson JL, Blakely EL, McFarland R, Taylor RW. Mitochondrial tRNA mutations and disease. Wiley Interdiscip Rev RNA. 2010;1(2):304–24.

[25]. Zhu J, Yang P, Liu X, Yan L, Rampersad S, Li F, Li H, Sheng C, Cheng X, Zhang M, Qu S. The clinical characteristics of patients with mitochondrial tRNA Leu(UUR)m.3243A > G mutation: Compared with type 1 diabetes and early onset type 2 diabetes. J Diabetes Complications. 2017;31(8):1354–1359.

[26]. Jiang Z, Zhang Y, Yan J, Li F, Geng X, Lu H, Wei X, Feng Y, Wang C, Jia W. De Novo Mutation of m.3243A>G together with m.16093T>C Associated with Atypical Clinical Features in a Pedigree with MIDD Syndrome. J Diabetes Res. 2019 Apr 4;2019:5184647

Tables
Table 1 Summary of clinical and biochemical data of members in one Chinese pedigree with T2DM.
| Subjects | Gender | Age at onset (yrs) | Fasting glucose (mmol/L) | Oral glucose tolerance (mmol/L) | HbA1c (%) |
|----------|--------|-------------------|--------------------------|--------------------------------|-----------|
| III-1    | M      | 50                | 16.1                     | 17.9                           | 7.7       |
| III-10   | F      | 36                | 9.1                      | 17.7                           | 6.2       |
| II-3     | M      | 58                | 10.1                     | 16.5                           | 7.1       |
| II-6     | F      | 56                | 11.3                     | 15.9                           | 7.3       |
| I-2      | F      | 85                | 6.8                      | 10.1                           | 5.9       |
| II-2     | F      | 61                | 6.5                      | 10.8                           | 5.3       |
| II-7     | M      | 55                | 6.5                      | 9.8                            | 4.1       |
| III-4    | F      | 46                | 6.7                      | 8.4                            | 3.8       |
| III-5    | M      | 38                | 4.8                      | 8.9                            | 4.6       |
| III-7    | M      | 35                | 5.1                      | 7.7                            | 5.1       |
| III-11   | M      | 27                | 5.6                      | 7.9                            | 4.3       |
| IV-2     | M      | 20                | 5.5                      | 8.3                            | 4.2       |
| IV-6     | F      | 19                | 4.2                      | 8.1                            | 4.8       |

Table 2. mtDNA variants in a Chinese pedigree with T2DM

| Gene               | Position CRS | Replacement | AA change | Conservation (H/B/M/X) | Previously reported a |
|--------------------|--------------|-------------|-----------|------------------------|-----------------------|
| D-loop 73 A        | G            | -           |           |                        | Yes                   |
| 146 T              | C            | -           |           |                        | Yes                   |
| 152 T              | C            | -           |           |                        | Yes                   |
| 249 A              | delA         | -           |           |                        | Yes                   |
| 263 A              | G            | -           |           |                        | Yes                   |
| 310 T              | CCTC         | -           |           |                        | Yes                   |
| 514-515 CA         | delCA        | -           |           |                        | Yes                   |
| 16304 T            | C            | -           |           |                        | Yes                   |
| 16519 T            | C            | -           |           |                        | Yes                   |
| 12S rRNA 750 A     | G            | -           | A/A/A/-   |                        | Yes                   |
| 1438 A             | G            | -           | A/A/A/G   |                        | Yes                   |
| Gene      | Position | Ref. | Mut. | Cons.  |
|-----------|----------|------|------|--------|
| 16S rRNA  | 1734 C   | T    | -    | C/C/C/T| Yes   |
|           | 2706 A   | G    | -    | A/G/A/A| Yes   |
|           | 3316 G   | A    | Ala-Thr | A/I/I/I| Yes   |
| ND1       | 3970 C   | T    | -    |        | Yes   |
| ND2       | 4769 A   | G    | -    |        | Yes   |
| tRNA^Ala  | 5628 T   | C    | -    | T/T/T/T| No    |
| CO1       | 6392 T   | C    | -    |        | Yes   |
|           | 6962 G   | A    | -    |        | Yes   |
|           | 7028 C   | T    | -    |        | Yes   |
|           | 7214 C   | T    | -    |        | Yes   |
|           | 7738 T   | C    | -    |        | Yes   |
| ATP6      | 8860 A   | G    | Thr-Ala | T/A/A/T| Yes   |
| CO3       | 10310 G  | A    | -    |        | Yes   |
| ND3       | 10609 T  | C    | Met-Thr | M/T/T/T| Yes   |
| ND4       | 11719 A  | G    | -    |        | Yes   |
| ND5       | 12406 G  | A    | Val-Ile|        | Yes   |
|           | 12882 C  | T    | -    |        | Yes   |
|           | 13928 G  | C    | Ser-Thr | S/T/S/T| Yes   |
|           | 14766 C  | T    | Thr-Ile | T/S/T/S| Yes   |
| ND6       | 15326 A  | G    | Thr-Ala | T/M/I/I| Yes   |
| Cytb      | 15402 C  | T    | Thr-Ile | T/P/P/P| Yes   |

a Conservation of amino acid for polypeptides or nucleotide for RNAs in human (H), bovine (B), mouse (M), and Xenopus laevis (X). b CRS, Cambridge reference sequence [20]. c See online mitochondrial genome databases http://www.mitomap.org and http://www.genpat.uu.se/mtDB/.

Figures
Figure 1

The Chinese pedigree with MDM. Vision-impaired individuals are indicated by blackened symbols.
Figure 2

Identification of the m.5628T>C mutation in the tRNA gene. Partial sequences chromatograms of tRNA gene from the proband and one Chinese control. An arrow indicates the location of the base changes at position 5628.
Figure 3

Northern blot analysis of mitochondrial tRNA. (A) Equal amounts of total mitochondrial RNA from various cell lines were electrophoresed through a denaturing polyacrylamide gel, electroblotted and hybridized with DIG-labeled oligonucleotide probes specific for the tRNAAla, tRNAThr, tRNAGlu, and tRNAHis, respectively. (B) Quantification of tRNA levels. Average relative tRNA content per cell, was normalized to the average content per cell of 5S rRNA in two mutant cell lines carrying the m.5628T>C variant and two control cell lines (SZC1, SZC2). The values for the latter are expressed as percentages of the average values for the control cell lines.
Figure 4

Western blot analysis of mitochondrial proteins. (A) Twenty micrograms of total cellular proteins from various cell lines were electrophoresed through a denaturing polyacrylamide gel, electroblotted and hybridized with respiratory complex subunits in mutant and control cells with VDAC as a loading control. (B) Quantification of 6 respiratory complex subunits. The levels of ND6, ND4, ATP6, and ND1 in two mutant cell lines and two control cell lines were determined. The error bars indicate two standard errors of the means. p indicates the significance, according to the t-test, of the differences between mutant and control cell lines.
mitochondrial ATP levels. Mutant and control cell lines were incubated with 10 mM glucose or 5 mM 2-deoxy-d-glucose plus 5 mM pyruvate to determine ATP generation under mitochondrial ATP synthesis. Average rates of ATP level per cell line in mitochondria are shown. The determinations were made for each cell line. The calculations were based on the independent determinations in each cell line.

![Graph showing membrane potential](image)

**A**

Controls

Mutations

$P=0.002$

**B**

$P=0.136$
Mitochondrial membrane potential analysis. The mitochondrial membrane potential ($\Delta \Psi_m$) was measured in mutant and control cell lines using a fluorescence probe JC-10 assay system. The ratio of fluorescence intensities Ex/Em=490/590 nm and 490/530 nm (FL590/FL530) were recorded to delineate the $\Delta \Psi_m$ level of each sample. The relative ratios of FL590/FL530 geometric mean between mutant and control cell lines were calculated to reflect the level of $\Delta \Psi_m$. Relative ratio of JC-10 fluorescence intensities at Ex/Em = 490/530 nm and 490/590 nm in absence and presence of 10$\mu$M of carbonyl cyanide 3-chlorophenylhydrazone (FCCP). The average of 3 determinations for each cell line is shown.
Figure 7

Ratio of geometric mean intensity. Measurement of mitoROS. The levels of ROS generation by mitochondria in living cells from mutant and control cell lines were determined using the mitochondrial superoxide indicator MitoSOX-Red. The average of the determinations for each cell line is shown. The error bars indicate two standard errors of the means. p indicates the significance, according to the t-test, of the differences between mutant and control cell lines.
